Annual Report 2012

Actelion Annual Report 2012

BACKGROUND STORIES

Actelion’s leadership in PAH is based on a history of innovation in the company from the laboratory to commercialization. These three articles give an insight into Actelion’s comprehensive knowledge base and strategy for the future.

Learn more

ACTELION TODAY

Actelion is a biopharmaceutical company with four products on the market. We are proud of our rich product pipeline which compares favorably to pharmaceutical companies of comparable size. Our team of more than 2,400 committed professionals around the world is passionate about transforming innovation into novel medicines.

Learn more

RESEARCH AND DEVELOPMENT

The excellent progress made with the company’s Research & Development pipeline in 2012 has validated Actelion’s approach of pursuing creative scientific innovation and evidence-based medicine.

Learn more

BUSINESS STRATEGY AND OPERATIONS

Our strong and effective commercial organization is currently preparing for the potential worldwide launch of macitentan. By providing this novel and differentiated ERA, Actelion is enabling the medical community to reshape the treatment paradigm for patients with PAH.

Learn more

CORPORATE SOCIAL RESPONSIBILITY

Our corporate responsibility commitments reflect the company’s mission to provide innovative medicines for unmet medical needs in a responsible, respectable and ethical manner.

Learn more

CORPORATE GOVERNANCE

Actelion's Articles of Association, its By-Laws and its Policy on Ethical Conduct, all provide the basis for its principles of Corporate Governance.

Learn more

COMPENSATION REPORT

A report that describes the compensation programs Actelion maintains for members of the Board and for senior executives, including the CEO.


Learn more

FINANCIAL REPORT

Actelion’s consolidated financial statements, including notes, management’s report on internal control over financial reporting; auditor statements as well as holding company statements including notes are all available in this section.

Learn more